Market cap
₹22 Cr
Revenue (TTM)
₹12 Cr
P/E Ratio
--
P/B Ratio
-3.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-4 Cr
-
ROE
0 %
-
ROCE
-29.9 %
-
Industry P/E
53.31
-
EV/EBITDA
-9.2
-
Debt to Equity
-1.9
-
Book Value
₹-18.3
-
EPS
₹-11.1
-
Face value
10
-
Shares outstanding
3,741,300
10 Years Aggregate
CFO
₹10.57 Cr
EBITDA
₹8.98 Cr
Net Profit
₹-6.56 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Parmax Pharma
| 75.3 | 81.2 | 105.6 | 52.3 | 26.1 | -3.8 | -- |
|
BSE Commodities
| 6.1 | -1.4 | 7.2 | 9.1 | 16.2 | 10.1 | 15.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Parmax Pharma
| -23.5 | 36.3 | -15.8 | -35.4 | 111.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Commodities
| 12.5 | 8.1 | 17.5 | 1.2 | 61.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Parmax Pharma
|
59.3 | 22.2 | 12.1 | -4.2 | -38.0 | -- | -- | -3.2 |
| 440.6 | 15,974.7 | 8,302.0 | 419.0 | 8.3 | 7.1 | 38.1 | 2.7 | |
| 1,142.9 | 15,183.2 | 1,153.5 | 219.5 | 25.6 | 9.5 | 69.2 | 6.2 | |
| 3,168.4 | 14,452.2 | 3,621.0 | 1,973.8 | 12.0 | 16.8 | 7.3 | 5.9 | |
| 1,669.9 | 22,779.0 | 7,887.1 | 550.7 | 9.6 | 9.9 | 41.4 | 3.9 | |
| 4,724.7 | 14,483.6 | 2,365.8 | 420.2 | 18.0 | 16 | 34.7 | 5.4 | |
| 680.5 | 34,316.4 | 4,660.7 | 755.1 | 19.2 | 18.1 | 45.7 | 7.3 | |
| 5.5 | 71.9 | 1.0 | 0.2 | -7.0 | 0.4 | 390.5 | 1.6 | |
| 216.5 | 17,500.6 | 8,051.9 | 575.8 | 9.3 | 8.8 | 29.7 | 2.6 | |
| 157.5 | 50.1 | 35.7 | 5.8 | 15.0 | 14.6 | 8.6 | 1.2 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Parmax Pharma
Manufacture of allopathic pharmaceutical preparations
-
Incorporated
1994
-
Chairman
--
-
Managing Director
Umang A Gosalia
-
Headquarters
Rajkot, Gujarat
-
Website
Annual Reports
Announcements
View AnnouncementsEGM Scheduled To Be Held On July 02 2026
09-Jun-2026Board Meeting Intimation for Fund Raising
03-Jun-2026Results-Delay in Financial Results
03-Jun-2026No News & Announcements are available.
FAQs for Parmax Pharma
What is the current share price of Parmax Pharma Ltd Today?
The share price of Parmax Pharma Ltd is ₹59.32 (BSE) as of 12-Jun-2026 IST. Parmax Pharma Ltd has given a return of 26.13% in the last 3 years.
What is the current PB & PE ratio of Parmax Pharma Ltd?
Since, TTM earnings of Parmax Pharma Ltd is negative, P/E ratio is not available.
The P/B ratio of Parmax Pharma Ltd is -3.24 times as on 12-Jun-2026, a 137 discount to its peers’ median range of 8.69 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
-5.86
|
|
2024
|
0.00
|
-17.63
|
|
2023
|
0.00
|
2.39
|
|
2022
|
108.00
|
3.43
|
|
2021
|
17.61
|
3.39
|
What is the 52 Week High and Low of Parmax Pharma Ltd?
The 52-week high and low of Parmax Pharma Ltd are Rs 59.32 and Rs 22.60 as of 13-Jun-2026.
What is the market cap of Parmax Pharma Ltd?
Parmax Pharma Ltd has a market capitalisation of ₹ 22 Cr as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Parmax Pharma Ltd?
Before investing in Parmax Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.